As Tecentriq Growth Slows, Roche’s Imminent TIGIT Readout Is Crucial

Aims To Challenge Keytruda Dominance

 
• By Andrew McConaghie
  
Roche_HQ
Roche's SKYSCRAPER 1 trial aims to improve on the overall survival benchmark set in NSCLC by Keytruda. • Source: Alamy

More from Business

More from Scrip